Cart
sales@molnova.com
Sibeprenlimab
CAS No. 2382896-07-1
Sibeprenlimab( —— )
Catalog No. M36868 CAS No. 2382896-07-1
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody that inhibits APRIL and may be investigated for the prevention and treatment of kidney disease (IgAN).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 588 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1387 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | 2474 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSibeprenlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody that inhibits APRIL and may be investigated for the prevention and treatment of kidney disease (IgAN).
-
DescriptionSibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL. Sibeprenlimab can be used for the research of IgA nephropathy (IgAN).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2382896-07-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mohit Mathur, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022 Feb 8;7(5):993-1003. ?
molnova catalog
related products
-
2''-O-Rhamnosylicari...
2''-O-Rhamnosylicariside II is beneficial for improving postmenopausal osteoporosis. It shows potent antioxidant activity, with IC50 values of 90.5 uM.
-
ethyl 1-(4-aminophen...
ethyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate is a chemical compound.
-
SEC inhibitor KL-2
SEC inhibitor KL-2 (KL-2) is a potent and selective inhibitor of the super elongation complex (SEC), showing a dose-dependent inhibitory effect on the AFF4-CCNT1 interaction with a Ki of 1.50 μM.
